Navigation Links
Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
Date:11/5/2007

corporate compliance program and which relates to clinical trials conducted at the hospital.

MedCath Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused on high acuity services with the diagnosis and treatment of cardiovascular disease being a primary service offering. MedCath owns interests in and operates eleven hospitals with a total of 667 licensed beds, located in Arizona, Arkansas, California, Louisiana, New Mexico, Ohio, South Dakota, and Texas. In addition, MedCath and its subsidiary MedCath Partners manage the cardiovascular program at various hospitals and provide services in diagnostic and therapeutic facilities in various states.


'/>"/>
SOURCE MedCath Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
2. Many Heart Attack Patients Dont Get Best Emergency Treatment
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
9. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
10. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
11. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2008)...- Bayer together with Nektar Therapeutics present ... treatment of pneumonia in intubated and ...TO and BERLIN, May 19 /- Ba...Nasdaq: NKTR ), today presented positive,prelimin...ination Amikacin,Inhale at the American Thoracic S...
(Date:5/19/2008)... - RDEA594 Data to Be Presented at the 2008 Annu... the European League Against Rheumatism (EULAR) -,...lanned in Second Half of ...tCall/ -- Ardea Biosciences, Inc.,(Nasdaq: RDEA )...velopment,candidate for the treatment of patients ...
(Date:5/19/2008)... MARSEILLE, France, May 19 /- IPSO...r that develops and markets molecular diagnostic,a...that researchers from,the University of Texas MD A...esent the results of two studies on the Genomic Gr...n Chicago from May 30 to June 3, 2008. The data,in...
(Date:5/18/2008)... -- Additional Data Demonstrated Higher Overall...and Symptom Relief versus Placebo --, SAN DIEGO, ... Inc.,today reported results from three pivotal Ph...TAK-390MR, the first proton pump inhibitor (PPI),w... in healing patients,with erosive esophagitis (EE)...
Breaking Medicine Technology:Amikacin Inhale Shows Promising Results in Phase II Study 2Amikacin Inhale Shows Promising Results in Phase II Study 3Amikacin Inhale Shows Promising Results in Phase II Study 4Amikacin Inhale Shows Promising Results in Phase II Study 5Amikacin Inhale Shows Promising Results in Phase II Study 6Amikacin Inhale Shows Promising Results in Phase II Study 7Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 2Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 3Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer 4TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 2TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 3TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis 4Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 1Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 2Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 3Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 4Isis Pharmaceuticals and Thomas McNerney 26 Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory 1281 5Rigel to Present Research Programs at Scientific Conferences 1279 1Rigel to Present Research Programs at Scientific Conferences 1279 2Rigel to Present Research Programs at Scientific Conferences 1279 3Targeted Nanoparticles Offer Promise in the Battle Against Cancer 529 1Targeted Nanoparticles Offer Promise in the Battle Against Cancer 529 2Why Healthy People Should Consider Individual Disability Insurance 3762 1Why Healthy People Should Consider Individual Disability Insurance 3762 2
(Date:5/20/2008)...elevised skin health program, the first of its kin... issues affecting an increasingly diverse,America,...ay, May 24, 2008., SAN FRANCISCO, May 20 /PRNewsw...ial designed to educate and inform the public abou...the Women,s Dermatologic Society (WDS),is pleased ...
(Date:5/20/2008)...ELMSFORD, Mass., May 20 /PRNewswire-FirstCall/ -- ... leading provider of specialized,high-performance...d signal,processing applications, announced that m...s business on Thursday, May 29, 2008 at the Cowen ...nce. The Conference will be,held at the New York P...
(Date:5/20/2008)...archers at the Peninsula Medical School in the Sou... San Raffaele Scientific Institute in Milan and Ca...ed a protein that is key to the regeneration of da...uld with further research lead to understanding di...de clues to methods of repairing damage in the cen...
(Date:5/20/2008)...ur years of paperless prescription use yields prac... health plans and policy makers, WASHINGTON, MAY ...th,Initiative (eHI) and the Center for Improving M...ate of a widely anticipated report detailing the,i... on physicians,consumers, employers, health plans...
Breaking Medicine News(10 mins):Health News:Women's Dermatologic Society Announces Collaboration on 'America's Ethnic Skin: An Al Roker Health Special' 2Health News:Women's Dermatologic Society Announces Collaboration on 'America's Ethnic Skin: An Al Roker Health Special' 3Health News:Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008 2Health News:Protein key to neuro-regeneration 2Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 2Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 3
... to explore the relationship between bicycle ridin...phasized whether or not a causal relationship exis... erectile dysfunction (disease). // However, it is...on according to Dr. Schrader, an expert in the fie...
...ata, not even sparing the city's upscale neighbour...ee has admitted that the fever that swept through ...fever. There have been reports of 4 casualties and...e of dengue in eight other people. The unofficial ...
... continues to daily kill a few more people in Utta...ring areas like Nepal. In this special report we r...ain fever and provide some essential information o... its life cycle and prevention. The first histo...
...mising with the life of its patients and selling e...ispensary says a latest report. The criminal opera...h exposed and captured unethical conduct on camera...those involved first went into denial mode immedia...
Other Medicine News:Health News:Brain Fever or Encephalitis Spreading in North India 2
...e beyond your investment., ,The Centiva/5 Critica...d time demands of the critical care environment. T... mind combining a compact size with high levels of...uable space around the patients bed and allows you...
...ther treatments for ,ED (e.g. Viagra, Injections...,Vacuum Therapy is gaining increasing ,popul...of the very positive associated benefits. ,In fa...ercise to prevent atrophy and to promote penile he...
...Mesh LP Self-Forming Plug is combining a lightweig... This results in a very soft hernia plug which sta...rd Plugs less foreign body material is included in... hernia size and shape allows for a softer and les...
...Mesh Self-Forming Plug is a mesh plug to treat lar...l hernias and femoralhernias. The self-expanding p...mpletely. Premilene Mesh Self-Forming Plug is a pr...h. The plug corresponds with all properties of Pre...
Medicine Products: